Drug class profile · refreshed daily from federal data

Aluminum Complex

3 molecules in this class, $186.8M combined CY2024 Part D spend across 3.5M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Aluminum Complex class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $186.8Mcombined across class
Total Rx claims: 3.5M1.4M unique beneficiaries
Generic mfrs (active): 13across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Sucralfate

Brand: Carafate · 3.5M Part D claims (CY24) · 1.4M beneficiaries · First FDA approval: 1981-10-30

13 generic mfrs 0 plans require PA

Low NADAC$0.114

→

Avg plan cost$0.369

Part D spend $186.8M 3× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Sucralfate Oral

Brand: Sucralfate · — Part D claims (CY24) · First FDA approval: 2019-12-02

Brand-only (no generics) 1 plans require PA

Low NADAC$0.117

→

Avg plan cost$0.117

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Sucralfate Oral Suspension

Brand: Sucralfate · — Part D claims (CY24) · First FDA approval: 2024-06-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.